Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Ampicillin | Research

First publication of endemic channels as part of a pediatric Antimicrobial Stewardship Program: when to turn on the alarms? Recommendations of a pediatric ASP program

Authors: Juan Pablo Londoño-Ruiz, Ivan Felipe Gutierrez-Tobar, Naddya Lheidy Bermúdez-Bohórquez, Andrea Esperanza Rodríguez

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

Pediatric Antimicrobial Stewardship Programs (ASP) consider DOT a fundamental measure to quantify the impact of ASP. Novel strategies have been described, but no endemic channels (EC) have been reported to compare antibiotic use within historical patterns. This report describes the process of constructing an EC and analyzing its interpretation.

Methods

This was a descriptive study of the construction, implementation, and analysis of EC. The median and quartile method, as well as the geometric mean (GM) and confidence interval (CI) methods using DOT for the last 4 years were used. ECs have also been elaborated on in critical services (PICU).

Results

GM and CI method seem to be more sensitive in identifying changes in antimicrobial use. Ceftriaxone increased its use starting in December 2021, reaching the warning zone in March 2022 in relation to increased cases of bacterial and complicated pneumonia. Piperacillin–tazobactam showed an important increase in PICU during the first 8 months of 2021, reaching the alert zone until August 2021; thereafter, its use decreased, and this variation was related to a modification in the presentation of complicated appendicitis during the COVID 19 pandemic restrictions. The use of ampicillin-sulbactam has increased since January 2022 because of a change in local guidelines regarding its use in appendicitis and peritonitis. The changes identified in each EC allowed ASP to take different conducts.

Conclusion

EC allowed us to construct a new tool to measure ASP impact, internal comparison of antibiotic use facilitated taking timely interventions. EC could be useful for all pediatric and adult ASP.
Literature
1.
go back to reference Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012;33(4):322–7. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012;33(4):322–7.
2.
go back to reference Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-77.CrossRef Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-77.CrossRef
3.
go back to reference Gerber JS, Jackson MA, Tamma PD, Zaoutis TE. Antibiotic stewardship in pediatrics. Pediatrics. 2021;147(1). Gerber JS, Jackson MA, Tamma PD, Zaoutis TE. Antibiotic stewardship in pediatrics. Pediatrics. 2021;147(1).
4.
go back to reference Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit. JAC Antimicrob Resist. 2019;1(3):dlz072. Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit. JAC Antimicrob Resist. 2019;1(3):dlz072.
5.
go back to reference Morris AM. Antimicrobial stewardship programs: appropriate measures and metrics to study their impact. Curr Treat Options Infect Dis. 2014;6(2):101–12.CrossRef Morris AM. Antimicrobial stewardship programs: appropriate measures and metrics to study their impact. Curr Treat Options Infect Dis. 2014;6(2):101–12.CrossRef
6.
go back to reference Science M, Timberlake K, Morris A, Read S, Le Saux N. Quality metrics for antimicrobial stewardship programs. Pediatrics. 2019;143(4). Science M, Timberlake K, Morris A, Read S, Le Saux N. Quality metrics for antimicrobial stewardship programs. Pediatrics. 2019;143(4).
7.
go back to reference Brotherton AL. Metrics of antimicrobial stewardship programs. Med Clin North Am. 2018;102(5):965–76.CrossRef Brotherton AL. Metrics of antimicrobial stewardship programs. Med Clin North Am. 2018;102(5):965–76.CrossRef
8.
go back to reference Hernández M, Arboleda D, Arce S, et al. Methodology to develop endemic channels and notification trends for dengue in Valle del Cauca, Colombia, 2009–2013. Biomedica. 2015;36:98–107.CrossRef Hernández M, Arboleda D, Arce S, et al. Methodology to develop endemic channels and notification trends for dengue in Valle del Cauca, Colombia, 2009–2013. Biomedica. 2015;36:98–107.CrossRef
9.
go back to reference Al-Hasan MN, Winders HR, Bookstaver PB, Justo JA. Direct measurement of performance: a new era in antimicrobial stewardship. Antibiotics (Basel). 2019;8(3). Al-Hasan MN, Winders HR, Bookstaver PB, Justo JA. Direct measurement of performance: a new era in antimicrobial stewardship. Antibiotics (Basel). 2019;8(3).
10.
go back to reference van Santen KL, Edwards JR, Webb AK, Pollack LA, O’Leary E, Neuhauser MM, et al. The standardized antimicrobial administration ratio: a new metric for measuring and comparing antibiotic use. Clin Infect Dis. 2018;67(2):179–85.CrossRef van Santen KL, Edwards JR, Webb AK, Pollack LA, O’Leary E, Neuhauser MM, et al. The standardized antimicrobial administration ratio: a new metric for measuring and comparing antibiotic use. Clin Infect Dis. 2018;67(2):179–85.CrossRef
11.
go back to reference Bortman M. Establishing endemic levels of ranges with computer spreadsheets. Rev Panam Salud Publica. 1999;5(1):1–8.CrossRef Bortman M. Establishing endemic levels of ranges with computer spreadsheets. Rev Panam Salud Publica. 1999;5(1):1–8.CrossRef
13.
go back to reference Amar S, Avni YS, O’Rourke N, Michael T. Prevalence of common infectious diseases after COVID-19 vaccination and easing of pandemic restrictions in Israel. JAMA Netw Open. 2022;5(2): e2146175.CrossRef Amar S, Avni YS, O’Rourke N, Michael T. Prevalence of common infectious diseases after COVID-19 vaccination and easing of pandemic restrictions in Israel. JAMA Netw Open. 2022;5(2): e2146175.CrossRef
14.
go back to reference Gutiérrez-Tobar IF, Londoño-Ruiz JP, Mariño-Drews C, Beltrán-Higuera S, Camacho-Moreno G, Leal-Castro AL, et al. Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008–2019. Vaccine. 2022;40(20):2875–83.CrossRef Gutiérrez-Tobar IF, Londoño-Ruiz JP, Mariño-Drews C, Beltrán-Higuera S, Camacho-Moreno G, Leal-Castro AL, et al. Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008–2019. Vaccine. 2022;40(20):2875–83.CrossRef
15.
go back to reference Orthopoulos G, Santone E, Izzo F, Tirabassi M, Pérez-Caraballo AM, Corriveau N, et al. Increasing incidence of complicated appendicitis during COVID-19 pandemic. Am J Surg. 2021;221(5):1056–60.CrossRef Orthopoulos G, Santone E, Izzo F, Tirabassi M, Pérez-Caraballo AM, Corriveau N, et al. Increasing incidence of complicated appendicitis during COVID-19 pandemic. Am J Surg. 2021;221(5):1056–60.CrossRef
16.
go back to reference Burgard M, Cherbanyk F, Nassiopoulos K, Malekzadeh S, Pugin F, Egger B. An effect of the COVID-19 pandemic: significantly more complicated appendicitis due to delayed presentation of patients! PLoS ONE. 2021;16(5):e0249171.CrossRef Burgard M, Cherbanyk F, Nassiopoulos K, Malekzadeh S, Pugin F, Egger B. An effect of the COVID-19 pandemic: significantly more complicated appendicitis due to delayed presentation of patients! PLoS ONE. 2021;16(5):e0249171.CrossRef
17.
go back to reference Wang AW, Prieto J, Ikeda DS, Lewis PR, Benzer EM, Van Gent JM. Perforated appendicitis: an unintended consequence during the coronavirus-19 pandemic. Mil Med. 2021;186(1–2):e94–7.CrossRef Wang AW, Prieto J, Ikeda DS, Lewis PR, Benzer EM, Van Gent JM. Perforated appendicitis: an unintended consequence during the coronavirus-19 pandemic. Mil Med. 2021;186(1–2):e94–7.CrossRef
Metadata
Title
First publication of endemic channels as part of a pediatric Antimicrobial Stewardship Program: when to turn on the alarms? Recommendations of a pediatric ASP program
Authors
Juan Pablo Londoño-Ruiz
Ivan Felipe Gutierrez-Tobar
Naddya Lheidy Bermúdez-Bohórquez
Andrea Esperanza Rodríguez
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07916-z

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine